Inclusion Criteria:
* 1\. Male or females patients in the range of class Class I to Class II obesity (30 ≤ BMI ≤ 39.9).
* Age between 18 and 65 years (both inclusive).
* Treatment naïve for bariatric surgery or endoscopic bariatric therapy.
* Patients that have been evaluated by the local MDT and have indication to ESG.
* Willingness to comply with the substantial behavioral modifications program as required by the procedure.
* Agree to avoid any use of weight loss medications such as Meridia, Saxenda, Januvia, Xenical, or over the counter weight loss medications or supplements throughout the study.
* Women of childbearing potential should have negative urine beta human chorionic gonadotropin (hCG) pregnancy test and must agree to use acceptable contraception methods throughout the study duration.
* Able to comply with study requirements and understand and sign the Informed Consent Form.
Exclusion Criteria:
* Previous upper GI surgery (except uncomplicated cholecystectomy or appendectomy), or other endoscopic bariatric procedures or conditions,
* Prior intra-gastric balloon or another gastric implant.
* History of a structural or functional disorder of the esophagus or pharynx that may impede passage of the device such as achalasia, stricture/stenosis, esophageal varices, esophageal diverticula, esophageal perforation, severe or intractable gastro-esophageal reflux symptoms while on maximal medical therapy, uncontrolled GERD defined as LA grade C esophagitis or greater.
* History of a structural or functional disorder of the stomach including gastric polyps \> 1 cm in size, gastroparesis, gastric ulcer, gastric cancer, chronic gastritis, gastric varices, hiatal hernia (\>4 cm) of axial displacement of the z-line above the diaphragm.
* Active H. pylori infection (subjects with active H. pylori may continue with the screening process if they are treated with an appropriate antibiotic regimen, and eradication has been confirmed).
* Patients with history of intestinal stricture/stenosis, small bowel or colonic obstruction or any other obstructive disorder of the GI tract such as adhesive peritonitis and/or abdominal adhesions.
* Patients with any inflammatory disease (IBD).
* Autoimmune disease, including but not limited to celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder.
* Active hepatitis, active liver disease, hepatic insufficiency , or cirrhosis.
* Untreated/inadequately treated hypothyroidism, defined as an elevated Thyroid-Stimulating Hormone (TSH) level at Screening; if on thyroid hormone replacement therapy, must be on stable dose for at least 6 weeks prior to Screening.
* Patients with PCOS (hormonal dis-balances).
* Persistent Anemia, defined as Hemoglobin \<10 g/dL.
* Significant cardiovascular disease including known history of valvular disease, or myocardial infarction, heart failure, transient ischemic attack or stroke within the last 6 months.
* Moderate or severe chronic kidney disease (CKD), with estimated glomerular filtration rate (eGFR) \<45 ml/min/1.73m2 (estimated by MDRD).
* Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, chemotherapy or radiotherapy within the past 12 months, who have clinically-significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the subject a poor candidate for clinical trial participation in the opinion of the Investigator.
* HbA1c \> 8.5 %.
* Patients requiring exogenous insulin.
* Use of glucose-lowering drugs for diabetes mellitus treatment with the exception of sulfonylurea (SU), biguanides and sodium dependent glucose co-transporter 2 (SGLT-2) inhibitors.
* Coagulopathy, congenital or acquired intestinal telangiectasia.
* Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
* Pregnant or breast-feeding woman.
* Patients with history or current abuse of drugs or alcohol.
* Patients who are taking medications that cause weight loss such as Meridia, Saxenda, Januvia, Xenical, or over the counter weight loss medications or supplements throughout the study.
* Patients who are taking medication that cause weight gain such as anti-depressants
* Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study.
* Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator.
